📋 Quick Summary
What FDA expects in a Warning Letter response: 15-day timeline, response structure, root cause analysis standard, CAPA closure evidence requirements, and common mistakes that keep Warning Letters open.
📬 Get daily updates like this in your inbox. Subscribe to RegWatch Daily →
The 15-Business-Day Timeline
FDA Warning Letters are public record from the moment they are posted on FDA.gov — which typically happens within a few days of issuance. Your 15-business-day response window starts when the letter is received at your registered facility address, not when someone opens it. This distinction matters: if your registered agent address is different from your operations address, your clock may already be running when your QA team first sees the letter.
The 15-business-day target is not a statutory deadline with automatic consequences, but failure to respond promptly is itself an aggravating factor. FDA tracks response timeliness. An initial response within 15 business days that commits to a corrective action timeline is significantly better than a comprehensive response delivered after 30 days.
What Your Response Must Include
A compliant Warning Letter response is not a denial or an explanation — it is a commitment. FDA reviewers are not looking for your interpretation of whether the cited observations are valid. They are looking for evidence that you understand the violation, have identified its root cause, and have implemented or committed to implement corrections with specific timelines and verification methodology.
Your response must address each cited observation individually. For each observation: acknowledge the finding, present your root cause analysis, describe the corrective action you have taken or will take, provide your completion timeline, and describe how you will verify effectiveness. Missing any of these components for any cited observation will generate a deficiency letter that restarts your timeline.
Root Cause Analysis Standard FDA Expects
FDA's expectation for root cause analysis in Warning Letter responses is higher than what most manufacturers use for internal CAPAs. The root cause must be systemic — not the immediate trigger event, but the QMS failure that allowed the trigger to occur and go undetected.
If FDA cited inadequate CAPA closure verification, the root cause is not that one CAPA was closed early. The root cause is the absence of a defined effectiveness verification methodology, or the failure of your management review process to detect the pattern, or both. Your RCA must go to that level. An RCA that concludes the root cause was human error or a one-time oversight will not satisfy FDA reviewers and will generate follow-up questions.
Get this intelligence in your inbox every morning.
Daily regulatory briefings for QA managers, SaMD teams, and startup RA leads — personalized, actionable, free.
Subscribe Free →Free forever. Unsubscribe anytime.
CAPA Closure Evidence Requirements
The most common reason Warning Letters remain open past their expected closure date is inadequate CAPA closure evidence. FDA reviewers require documented evidence that your corrective actions were implemented, verified as effective, and integrated into your quality system — not just completed on paper.
For each CAPA commitment in your response, FDA expects: objective evidence that the corrective action was implemented (training records, updated procedures, inspection records), evidence that the implementation was verified (audit results, test data, sampling records), and evidence that the effectiveness of the correction was evaluated against a predefined metric. Providing only the corrective action documentation without the effectiveness evidence is the single most common mistake that extends Warning Letter timelines.
📚 Sources & References
Get this intelligence in your inbox every morning.
Daily regulatory briefings for QA managers, SaMD teams, and startup RA leads — personalized, actionable, free.
Subscribe Free →Free forever. Unsubscribe anytime.
Get the FDA Warning Letter Response Toolkit — triage checklist, RCA template, CAPA template, response letter format, and closure evidence package.
Get the FDA Warning Letter Response Toolkit — $297